nach oben

International Journal of Colorectal Disease

Erschienen in:

01.09.2011 | Original Article

Interaction between CTLA4 gene and IBD5 locus in Hungarian Crohn’s disease patients

verfasst von: Veronika Csöngei, Luca Járomi, Enikő Sáfrány, Csilla Sipeky, Lili Magyari, Noémi Polgár, Judit Bene, Patrícia Sarlós, Lilla Lakner, Eszter Baricza, Melinda Szabó, Gábor Rappai, Béla Melegh

Erschienen in: International Journal of Colorectal Disease | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Backgrounds and aims

The IGR2198a_1 and IGR2096a_1 variants of the IBD5 region were found to be associated with Crohn’s disease (CD) in the Hungarian population, while IGR2230a_1 does not seem to confer risk for the disease. In the present study, our aim was to investigate the statistical interaction of these three IBD5 polymorphisms with the +49 A/G substitution within the cytotoxic T lymphocyte antigen-4 (CTLA4) gene, detected previously as neutral gene variant in Hungarian IBD patients.

Methods

A total of 305 unrelated subjects with CD and 310 healthy controls were genotyped with PCR-RFLP methods.

Results

In contrast with single gene effects, after genotype stratification, the IGR2198a_1 C and IGR2096a_1 T variants were found to confer susceptibility only in subjects with CTLA4 +49 AA genotype (P = 0.008; OR = 1.86 and P = 0.016; OR = 1.74, respectively), for IGR2230a_1 no such effect on disease risk could be demonstrated.

Conclusion

Analysis of specific genotype combinations unfolded a possible association between the CTLA4 +49 A/G substitution and two of the observed IBD5 variants with respect to disease risk.

Moore JH (2003) The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 56:73–82PubMedCrossRef

Cordell HJ (2002) Epistasis: what it means, what it doesn’t mean, and statistical methods to detect it in humans. Hum Mol Genet 11:2463–2468PubMedCrossRef

Magyari L, Farago B, Bene J et al (2007) No association of the cytotoxic T-lymphocyte associated gene CTLA4 +49A/G polymorphisms with Crohn’s disease and ulcerative colitis in Hungarian population samples. World J Gastroenterol 13:2205–2208PubMed

Talian G, Lakner L, Bene J et al (2009) Plasma carnitine ester profiles in Crohn’s disease and ulcerative colitis patients with different IGR2230a_1 genotypes. Int J Immunogenet 36:329–335PubMedCrossRef

Lakner L, Csongei V, Sarlos P et al (2009) IGR2096a_1 T and IGR2198a_1 C alleles on IBD5 locus of chromosome 5q31 region confer risk for Crohn’s disease in Hungarian patients. Int J Colorectal Dis 24:503–507PubMedCrossRef

Culverhouse R, Suarez BK, Lin J, Reich T (2002) A perspective on epistasis: limits of models displaying no main effect. Am J Hum Genet 70:461–471PubMedCrossRef

Hampe J, Franke A, Rosenstiel P et al (2007) A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 39:207–211PubMedCrossRef

Safrany E, Melegh B (2009) Functional variants of the interleukin-23 receptor gene in non-gastrointestinal autoimmune diseases. Curr Med Chem 16:3766–3774PubMedCrossRef

Farago B, Magyari L, Safrany E et al (2008) Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Ann Rheum Dis 67:248–250PubMedCrossRef

10.

Cummings JR, Cooney R, Pathan S et al (2007) Confirmation of the role of ATG16L1 as a Crohn’s disease susceptibility gene. Inflamm Bowel Dis 13:941–946PubMedCrossRef

11.

Prescott NJ, Fisher SA, Franke A et al (2007) A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn’s disease and is independent of CARD15 and IBD5. Gastroenterology 132:1665–1671PubMedCrossRef

12.

Glas J, Konrad A, Schmechel S et al (2008) The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn’s disease in the German population. Am J Gastroenterol 103:682–691PubMedCrossRef

13.

Latiano A, Palmieri O, Valvano MR et al (2008) Replication of interleukin 23 receptor and autophagy-related 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy. World J Gastroenterol 14:4643–4651PubMedCrossRef

14.

Roberts RL, Gearry RB, Hollis-Moffatt JE et al (2007) IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn’s disease in a study of New Zealand Caucasians with inflammatory bowel disease. Am J Gastroenterol 102:2754–2761PubMedCrossRef

15.

Glas J, Seiderer J, Wetzke M et al (2007) rs1004819 is the main disease-associated IL23R variant in German Crohn’s disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS ONE 2:e819PubMedCrossRef

16.

Latiano A, Palmieri O, Valvano RM et al (2006) Contribution of IBD5 locus to clinical features of IBD patients. Am J Gastroenterol 101:318–325PubMedCrossRef

17.

Weersma RK, Stokkers PC, van Bodegraven AA et al (2009) Molecular prediction of disease risk and severity in a large Dutch Crohn’s disease cohort. Gut 58:388–395PubMedCrossRef

18.

Csongei V, Jaromi L, Safrany E et al (2010) Interaction of the major inflammatory bowel disease susceptibility alleles in Crohn’s disease patients. World J Gastroenterol 16:176–183PubMedCrossRef

19.

Okazaki T, Wang MH, Rawsthorne P et al (2008) Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn’s disease risk in a population-based case-control study: evidence of gene-gene interactions. Inflamm Bowel Dis 14:1528–1541PubMedCrossRef

20.

Petermann I, Huebner C, Browning BL et al (2009) Interactions among genes influencing bacterial recognition increase IBD risk in a population-based New Zealand cohort. Hum Immunol 70:440–446PubMedCrossRef

21.

McGovern DP, Rotter JI, Mei L et al (2009) Genetic epistasis of IL23/IL17 pathway genes in Crohn’s disease. Inflamm Bowel Dis 15:883–889PubMedCrossRef

22.

Marquez A, Varade J, Robledo G et al (2009) Specific association of a CLEC16A/KIAA0350 polymorphism with NOD2/CARD15(−) Crohn’s disease patients. Eur J Hum Genet 17:1304–1308PubMedCrossRef

23.

Machida H, Tsukamoto K, Wen CY et al (2005) Association of polymorphic alleles of CTLA4 with inflammatory bowel disease in the Japanese. World J Gastroenterol 11:4188–4193PubMed

24.

Ben Alaya W, Sfar I, Aouadi H et al (2009) Association between CTLA-4 gene promoter (49 A/G) in exon 1 polymorphisms and inflammatory bowel disease in the Tunisian population. Saudi J Gastroenterol 15:29–34PubMedCrossRef

25.

Xia B, Crusius JB, Wu J, Zwiers A, van Bodegraven AA, Pena AS (2002) CTLA4 gene polymorphisms in Dutch and Chinese patients with inflammatory bowel disease. Scand J Gastroenterol 37:1296–1300PubMedCrossRef

26.

Hou W, Xia B, Yuan A, Li J, Yang Z, Mao L (2005) CTLA-4 gene polymorphisms in Chinese patients with ulcerative colitis. Inflamm Bowel Dis 11:653–656PubMedCrossRef

27.

Lankarani KB, Karbasi A, Kalantari T et al (2006) Analysis of cytotoxic T lymphocyte associated antigen 4 gene polymorphisms in patients with ulcerative colitis. J Gastroenterol Hepatol 21:449–453PubMedCrossRef

28.

Hradsky O, Dusatkova P, Lenicek M et al (2010) The CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in the development of Crohn’s disease. BMC Med Genet 11:91PubMedCrossRef

29.

Abe T, Takino H, Yamasaki H et al (1999) CTLA4 gene polymorphism correlates with the mode of onset and presence of ICA512 Ab in Japanese type 1 diabetes. Diabetes Res Clin Pract 46:169–175PubMedCrossRef

30.

Cinek O, Drevinek P, Sumnik Z et al (2002) The CTLA4 +49 A/G dimorphism is not associated with type 1 diabetes in Czech children. Eur J Immunogenet 29:219–222PubMedCrossRef

31.

Donner H, Rau H, Walfish PG et al (1997) CTLA4 alanine-17 confers genetic susceptibility to Graves’ disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab 82:143–146PubMedCrossRef

32.

Lee YJ, Huang FY, Lo FS et al (2000) Association of CTLA4 gene A-G polymorphism with type 1 diabetes in Chinese children. Clin Endocrinol 52:153–157CrossRef

33.

Nistico L, Buzzetti R, Pritchard LE et al (1996) The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 5:1075–1080PubMedCrossRef

34.

Osei-Hyiaman D, Hou L, Zhiyin R et al (2001) Association of a novel point mutation (C159G) of the CTLA4 gene with type 1 diabetes in West Africans but not in Chinese. Diabetes 50:2169–2171PubMedCrossRef

35.

Zalloua PA, Abchee A, Shbaklo H et al (2004) Patients with early onset of type 1 diabetes have significantly higher GG genotype at position 49 of the CTLA4 gene. Hum Immunol 65:719–724PubMedCrossRef

36.

Lemos MC, Coutinho E, Gomes L et al (2009) The CTLA4 +49 A/G polymorphism is not associated with susceptibility to type 1 diabetes mellitus in the Portuguese population. Int J Immunogenet 36:193–195PubMedCrossRef

37.

Borhani HA, Ghahramani S, Azarpira N, Pourjafar M, Nikseresht AR (2008) Cytotoxic T lymphocyte associated antigen-4 exon 1 A/G polymorphism in Iranian patients with multiple sclerosis. Eur J Neurol 15:862–864CrossRef

38.

Heggarty S, Suppiah V, Silversides J et al (2007) CTLA4 gene polymorphisms and multiple sclerosis in Northern Ireland. J Neuroimmunol 187:187–191PubMedCrossRef

39.

Yousefipour G, Erfani N, Momtahan M, Moghaddasi H, Ghaderi A (2009) CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis. Acta Neurol Scand 120:424–429PubMedCrossRef

40.

Bilinska M, Frydecka I, Noga L et al (2004) Progression of multiple sclerosis is associated with exon 1 CTLA-4 gene polymorphism. Acta Neurol Scand 110:67–71PubMedCrossRef

41.

Heward JM, Allahabadia A, Armitage M et al (1999) The development of Graves’ disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab 84:2398–2401PubMedCrossRef

42.

Kinjo Y, Takasu N, Komiya I et al (2002) Remission of Graves’ hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene. J Clin Endocrinol Metab 87:2593–2596PubMedCrossRef

43.

Kouki T, Gardine CA, Yanagawa T, DeGroot LJ (2002) Relation of three polymorphisms of the CTLA-4 gene in patients with Graves’ disease. J Endocrinol Investig 25:208–213

44.

Ueda H, Howson JM, Esposito L et al (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506–511PubMedCrossRef

45.

Wang PW, Liu RT, Juo SH et al (2004) Cytotoxic T lymphocyte-associated molecule-4 polymorphism and relapse of Graves’ hyperthyroidism after antithyroid withdrawal. J Clin Endocrinol Metab 89:169–173PubMedCrossRef

46.

Donner H, Braun J, Seidl C et al (1997) Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto’s thyroiditis and Addison’s disease. J Clin Endocrinol Metab 82:4130–4132PubMedCrossRef

47.

Gonzalez-Escribano MF, Rodriguez R, Valenzuela A, Garcia A, Garcia-Lozano JR, Nunez-Roldan A (1999) CTLA4 polymorphisms in Spanish patients with rheumatoid arthritis. Tissue Antigens 53:296–300PubMedCrossRef

48.

Lee CS, Lee YJ, Liu HF et al (2003) Association of CTLA4 gene A-G polymorphism with rheumatoid arthritis in Chinese. Clin Rheumatol 22:221–224PubMedCrossRef

49.

Barreto M, Santos E, Ferreira R et al (2004) Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet 12:620–626PubMedCrossRef

50.

Djilali-Saiah I, Schmitz J, Harfouch-Hammoud E, Mougenot JF, Bach JF, Caillat-Zucman S (1998) CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Gut 43:187–189PubMedCrossRef

51.

Naluai AT, Nilsson S, Samuelsson L et al (2000) The CTLA4/CD28 gene region on chromosome 2q33 confers susceptibility to celiac disease in a way possibly distinct from that of type 1 diabetes and other chronic inflammatory disorders. Tissue Antigens 56:350–355PubMedCrossRef

52.

King AL, Moodie SJ, Fraser JS et al (2003) Coeliac disease: investigation of proposed causal variants in the CTLA4 gene region. Eur J Immunogenet 30:427–432PubMedCrossRef

53.

Martin-Pagola A, Perez dN, Vitoria JC et al (2003) No association of CTLA4 gene with celiac disease in the Basque population. J Pediatr Gastroenterol Nutr 37:142–145PubMedCrossRef

54.

Popat S, Hearle N, Wixey J et al (2002) Analysis of the CTLA4 gene in Swedish coeliac disease patients. Scand J Gastroenterol 37:28–31PubMedCrossRef

55.

Popat S, Hearle N, Hogberg L et al (2002) Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease. Ann Hum Genet 66:125–137PubMedCrossRef

56.

Mora B, Bonamico M, Indovina P et al (2003) CTLA-4 +49 A/G dimorphism in Italian patients with celiac disease. Hum Immunol 64:297–301PubMedCrossRef

57.

Gudjonsdottir AH, Nilsson S, Naluai AT et al (2009) Association between genotypes and phenotypes in coeliac disease. J Pediatr Gastroenterol Nutr 49:165–169PubMedCrossRef

58.

Suppiah V, Alloza I, Heggarty S et al (2005) The CTLA4 +49 A/G*G-CT60*G haplotype is associated with susceptibility to multiple sclerosis in Flanders. J Neuroimmunol 164:148–153PubMedCrossRef

59.

Suppiah V, O'Doherty C, Heggarty S, Patterson CC, Rooney M, Vandenbroeck K (2006) The CTLA4+49A/G and CT60 polymorphisms and chronic inflammatory arthropathies in Northern Ireland. Exp Mol Pathol 80:141–146PubMedCrossRef

60.

Downie-Doyle S, Bayat N, Rischmueller M, Lester S (2006) Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren’s syndrome. Arthritis Rheum 54:2434–2440PubMedCrossRef

61.

Hunt KA, McGovern DP, Kumar PJ et al (2005) A common CTLA4 haplotype associated with coeliac disease. Eur J Hum Genet 13:440–444PubMedCrossRef

62.

Amundsen SS, Naluai AT, Ascher H et al (2004) Genetic analysis of the CD28/CTLA4/ICOS (CELIAC3) region in coeliac disease. Tissue Antigens 64:593–599PubMedCrossRef

63.

Seidl C, Donner H, Fischer B et al (1998) CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens 51:62–66PubMedCrossRef

64.

Jung MH, Yu J, Shin CH, Suh BK, Yang SW, Lee BC (2009) Association of cytotoxic T lymphocyte antigen-4 gene polymorphisms and HLA class II alleles with the development of type 1 diabetes in Korean children and adolescents. J Korean Med Sci 24:1004–1009PubMedCrossRef

65.

Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF, Golstein P (1991) CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 147:1037–1044PubMed

66.

Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA (1996) CTLA-4: a negative regulator of autoimmune disease. J Exp Med 184:783–788PubMedCrossRef

67.

Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533–2540PubMedCrossRef

68.

Alegre ML, Shiels H, Thompson CB, Gajewski TF (1998) Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 161:3347–3356PubMed

69.

Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ (2000) CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves’ disease. J Immunol 165:6606–6611PubMed

70.

Maurer M, Loserth S, Kolb-Maurer A et al (2002) A polymorphism in the human cytotoxic T-lymphocyte antigen 4 ( CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 54:1–8PubMedCrossRef

Titel: Interaction between CTLA4 gene and IBD5 locus in Hungarian Crohn’s disease patients
verfasst von: Veronika Csöngei
Luca Járomi
Enikő Sáfrány
Csilla Sipeky
Lili Magyari
Noémi Polgár
Judit Bene
Patrícia Sarlós
Lilla Lakner
Eszter Baricza
Melinda Szabó
Gábor Rappai
Béla Melegh
Publikationsdatum: 01.09.2011
Verlag: Springer-Verlag
Erschienen in: International Journal of Colorectal Disease / Ausgabe 9/2011
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-011-1202-z

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Backgrounds and aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2011

Meta-analysis of associations between polymorphisms in the promoter regions of matrix metalloproteinases and the risk of colorectal cancer

Polymorphisms of Caspase 8 and Caspase 9 gene and colorectal cancer susceptibility and prognosis

Retroperitoneal air after percutaneous nerve evaluation for irritable bowel syndrome

Unique abscess in ulcerative colitis

Medium-term results of anal advancement flap compared with lateral sphincterotomy for the treatment of anal fissure

Laparoscopic colectomy is feasible in patients with left ventricular assist devices

Update Chirurgie